文献速递消化、代谢与肾脏急症心脑血管急症重症综合管理与镇静镇痛

重度高钾血症所致严重心动过缓:患者特征、结局及与血流动力学支持相关的因素

Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support.
PubMed 文献 · Am J Emerg Med · 2022-03-10
一句话结论急诊重度高钾血症合并严重心动过缓(心率<50次/分、血钾≥6.0 mEq/L)患者中38%需血流动力学支持,透析依赖者接受针对性治疗的可能性较低。

该回顾性单中心病例系列纳入2014年1月1日至2020年6月30日急诊同时出现严重心动过缓(心率<50次/分)与重度高钾血症(血钾≥6.0 mEq/L)的成人患者87例,平均年龄72.5岁,55%为女性,中位心率43次/分,平均血钾7.1 mEq/L。38%接受血流动力学支持(14%需临时心脏起搏),48%接受紧急肾脏替代治疗,66%入住ICU,院内死亡率10%。与接受血流动力学靶向治疗相关的因素包括非透析依赖、交界性心律,以及合并低体温、酸血症或脓毒症。作者认为该表型患者可能需要大量复苏和重症监护资源,并需进一步研究。

要点

  • 纳入标准:急诊成人同时严重心动过缓(心率<50次/分)与重度高钾血症(血钾≥6.0 mEq/L),共87例。
  • 38%患者接受血流动力学支持,其中14%需临时心脏起搏;48%接受紧急肾脏替代治疗,66%入住ICU。
  • 院内死亡率为10%;32%就诊时存在低血压,40%存在意识状态改变。
  • 与接受血流动力学靶向治疗相关的因素:非透析依赖、交界性心律、合并低体温/酸血症/脓毒症。
  • 84%患者长期使用负性变时药物,52%使用保钾药物;常见诱因为漏透析、单纯急性肾衰竭或急性肾衰竭合并危重症。

适用人群与场景

  • 2014年1月1日至2020年6月30日某城市三级医院急诊就诊的成人患者,同时存在严重心动过缓(心率<50次/分)与重度高钾血症(血钾≥6.0 mEq/L),连续纳入。
  • 排除:院前心脏骤停、血钾标本溶血、仅有床旁即时检验结果的患者。

诊断标准与关键阈值

  • 严重心动过缓定义为心率<50次/分;重度高钾血症定义为血钾≥6.0 mEq/L。

红旗征与不能漏的情况

  • 32%患者就诊时存在低血压,40%存在意识状态改变。
  • 心电图表现:交界性心律39%、T波高尖27%、QRS波延长30%。

研究设计与关键结果

  • 回顾性单中心病例系列,筛查319份记录,纳入87例;平均年龄72.5岁(95%CI 53-92),55%为女性,中位心率43次/分(38-47),平均血钾7.1 mEq/L(95%CI 5.6-8.7)。
  • 合并症:高血压82%、充血性心力衰竭28%、透析依赖30%;84%长期使用负性变时药物,52%使用保钾药物。
  • 常见就诊场景为漏透析、单纯急性肾衰竭或急性肾衰竭合并危重症。
  • 33例(38%)接受血流动力学支持,其中12例(14%)需临时心脏起搏;42例(48%)接受紧急肾脏替代治疗;57例(66%)入住ICU;院内死亡率10%。
  • 与接受血流动力学靶向治疗相关的因素包括非透析依赖、交界性心律,以及合并低体温、酸血症或脓毒症(单因素比较)。

证据类型、等级与局限

  • 证据类型:回顾性、单中心病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,急诊同时出现严重心动过缓与重度高钾血症的患者可能需要大量复苏和重症监护资源。
  • 作者认为,需进一步研究这一不常见但可能危及生命的状况的治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Bradycardia is an under-studied manifestation of hyperkalemia potentially associated with adverse outcomes. We sought to systematically describe emergency department (ED) patients that present with severe bradycardia (heart rate < 50) associated with severe hyperkalemia (potassium ≥6.0 mEQ/L) and identify factors associated with the receipt of hemodynamic support.

METHODS: Retrospective, single-center, case series performed at an urban, tertiary-care hospital from 1/1/2014 to 6/30/2020. We included consecutive adult ED patients presenting simultaneously with severe bradycardia and severe hyperkalemia. Patients with prehospital cardiac arrest, hemolyzed potassium specimens, or only point-of-care lab results were excluded. Detailed information, including chronic medications, electrocardiogram (ECG) features, and potassium/heart rate-directed treatments, was abstracted from the ED medical record. Intensive care utilization and in-hospital outcomes were also recorded. Factors associated with receipt of bradycardia-targeted treatment in the ED were determined with univariate comparisons.

RESULTS: We screened 319 records and included 87 patients [mean age 72.5 (95% CI 53-92), 55% female, median heart rate 43 (38-47) beats/min, mean potassium 7.1 (95% CI 5.6-8.7) mEQ/L]. Cardiovascular (hypertension 82%, congestive heart failure 28%) and renal (dialysis dependence 30%) comorbidities were common. Many patients were prescribed negative chronotropic agents (84%) or potassium-retaining (52%) chronic medications. Common presenting scenarios were missed hemodialysis, isolated acute renal failure, or acute renal failure in the setting of concomitant critical illness. ECG revealed: junctional rhythm (39%), peaked T waves (27%), and QRS prolongation (30%). Twenty-eight (32%) patients exhibited hypotension and 34 (40%) altered mentation. Thirty-three (38%) patients received hemodynamic support, including 12 (14%) requiring temporary cardiac pacing. Forty-two (48%) patients received emergent renal replacement therapy and 57 (66%) were admitted to the intensive care unit. Hospital mortality was 10%. Factors associated with receipt of hemodynamic-targeted treatment included a lack of dialysis dependence, junctional rhythm, and concomitant presentation with hypothermia, acidemia, or sepsis.

CONCLUSIONS: Patients presenting with severe bradycardia represent a unique phenotype of ED patients with hyperkalemia that may require significant resuscitation and critical care resources. Further research on the treatment of this uncommon, but potentially life-threatening condition is needed.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Drumheller BC, Tuffy E, Gibney F, et al. Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support. Am J Emerg Med. 2022. PMID: 35306438. doi:10.1016/j.ajem.2022.03.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。